Global and United States Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size, Status and Forecast 2023-2027

Report ID: 1014697 | Published Date: Jan 2025 | No. of Page: 106 | Base Year: 2024 | Rating: 5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Nonselective MAO-Ainhibitors
        1.2.3 Selective MAO-B inhibitors
        1.2.4 Nonselective MAO-B inhibitors
    1.3 Market by Application
        1.3.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Depression Treatment
        1.3.3 Parkinson's Disease Treatment
        1.3.4 Other Therapy
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Perspective (2016-2027)
    2.2 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Growth Trends by Regions
        2.2.1 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Historic Market Share by Regions (2016-2021)
        2.2.3 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecasted Market Size by Regions (2022-2027)
    2.3 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Industry Dynamic
        2.3.1 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Trends
        2.3.2 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Drivers
        2.3.3 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Challenges
        2.3.4 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Reversible Inhibitors of Monoamine (RIMA) Antidepressants Players by Revenue
        3.1.1 Global Top Reversible Inhibitors of Monoamine (RIMA) Antidepressants Players by Revenue (2016-2021)
        3.1.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Players (2016-2021)
    3.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue
    3.4 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Concentration Ratio
        3.4.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue in 2020
    3.5 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Key Players Head office and Area Served
    3.6 Key Players Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Solution and Service
    3.7 Date of Enter into Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Breakdown Data by Type
    4.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Historic Market Size by Type (2016-2021)
    4.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecasted Market Size by Type (2022-2027)

5 Reversible Inhibitors of Monoamine (RIMA) Antidepressants Breakdown Data by Application
    5.1 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Historic Market Size by Application (2016-2021)
    5.2 Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (2016-2027)
    6.2 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type
        6.2.1 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021)
        6.2.2 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2022-2027)
        6.2.3 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2027)
    6.3 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application
        6.3.1 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2021)
        6.3.2 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2022-2027)
        6.3.3 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2027)
    6.4 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country
        6.4.1 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2016-2021)
        6.4.2 North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (2016-2027)
    7.2 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type
        7.2.1 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021)
        7.2.2 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2022-2027)
        7.2.3 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2027)
    7.3 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application
        7.3.1 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2021)
        7.3.2 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2022-2027)
        7.3.3 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2027)
    7.4 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country
        7.4.1 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2016-2021)
        7.4.2 Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (2016-2027)
    8.2 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type
        8.2.1 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2027)
    8.3 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application
        8.3.1 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2027)
    8.4 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Region
        8.4.1 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (2016-2027)
    9.2 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type
        9.2.1 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021)
        9.2.2 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2022-2027)
        9.2.3 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2027)
    9.3 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application
        9.3.1 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2021)
        9.3.2 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2022-2027)
        9.3.3 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2027)
    9.4 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country
        9.4.1 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2016-2021)
        9.4.2 Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (2016-2027)
    10.2 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type
        10.2.1 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2027)
    10.3 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application
        10.3.1 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2027)
    10.4 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country
        10.4.1 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Alkermes Plc
        11.1.1 Alkermes Plc Company Details
        11.1.2 Alkermes Plc Business Overview
        11.1.3 Alkermes Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
        11.1.4 Alkermes Plc Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
        11.1.5 Alkermes Plc Recent Development
    11.2 Allergan Plc
        11.2.1 Allergan Plc Company Details
        11.2.2 Allergan Plc Business Overview
        11.2.3 Allergan Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
        11.2.4 Allergan Plc Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
        11.2.5 Allergan Plc Recent Development
    11.3 Bristol Myers Squibb Co.
        11.3.1 Bristol Myers Squibb Co. Company Details
        11.3.2 Bristol Myers Squibb Co. Business Overview
        11.3.3 Bristol Myers Squibb Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
        11.3.4 Bristol Myers Squibb Co. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
        11.3.5 Bristol Myers Squibb Co. Recent Development
    11.4 Eli Lilly& Co.
        11.4.1 Eli Lilly& Co. Company Details
        11.4.2 Eli Lilly& Co. Business Overview
        11.4.3 Eli Lilly& Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
        11.4.4 Eli Lilly& Co. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
        11.4.5 Eli Lilly& Co. Recent Development
    11.5 GlaxoSmithKline Plc
        11.5.1 GlaxoSmithKline Plc Company Details
        11.5.2 GlaxoSmithKline Plc Business Overview
        11.5.3 GlaxoSmithKline Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
        11.5.4 GlaxoSmithKline Plc Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
        11.5.5 GlaxoSmithKline Plc Recent Development
    11.6 H. Lundbeck
        11.6.1 H. Lundbeck Company Details
        11.6.2 H. Lundbeck Business Overview
        11.6.3 H. Lundbeck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
        11.6.4 H. Lundbeck Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
        11.6.5 H. Lundbeck Recent Development
    11.7 Merck
        11.7.1 Merck Company Details
        11.7.2 Merck Business Overview
        11.7.3 Merck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
        11.7.4 Merck Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
        11.7.5 Merck Recent Development
    11.8 Pfizer
        11.8.1 Pfizer Company Details
        11.8.2 Pfizer Business Overview
        11.8.3 Pfizer Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
        11.8.4 Pfizer Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
        11.8.5 Pfizer Recent Development
    11.9 Teva Pharmaceutical Industries Ltd.
        11.9.1 Teva Pharmaceutical Industries Ltd. Company Details
        11.9.2 Teva Pharmaceutical Industries Ltd. Business Overview
        11.9.3 Teva Pharmaceutical Industries Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
        11.9.4 Teva Pharmaceutical Industries Ltd. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
        11.9.5 Teva Pharmaceutical Industries Ltd. Recent Development
    11.10 Takeda Pharmaceutical Co. Ltd.
        11.10.1 Takeda Pharmaceutical Co. Ltd. Company Details
        11.10.2 Takeda Pharmaceutical Co. Ltd. Business Overview
        11.10.3 Takeda Pharmaceutical Co. Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Introduction
        11.10.4 Takeda Pharmaceutical Co. Ltd. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
        11.10.5 Takeda Pharmaceutical Co. Ltd. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Nonselective MAO-Ainhibitors
    Table 3. Key Players of Selective MAO-B inhibitors
    Table 4. Key Players of Nonselective MAO-B inhibitors
    Table 5. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Regions (2016-2021) & (US$ Million)
    Table 8. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Regions (2016-2021)
    Table 9. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 10. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Regions (2022-2027)
    Table 11. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Trends
    Table 12. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Drivers
    Table 13. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Challenges
    Table 14. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Restraints
    Table 15. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue by Players (2016-2021) & (US$ Million)
    Table 16. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Players (2016-2021)
    Table 17. Global Top Reversible Inhibitors of Monoamine (RIMA) Antidepressants Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants as of 2020)
    Table 18. Ranking of Global Top Reversible Inhibitors of Monoamine (RIMA) Antidepressants Companies by Revenue (US$ Million) in 2020
    Table 19. Global 5 Largest Players Market Share by Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue (CR5 and HHI) & (2016-2021)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product Solution and Service
    Table 22. Date of Enter into Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021) (US$ Million)
    Table 25. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Type (2016-2021)
    Table 26. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 27. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 28. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size Share by Application (2016-2021) & (US$ Million)
    Table 29. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Application (2016-2021)
    Table 30. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 31. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 32. North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021) (US$ Million)
    Table 33. North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2022-2027) & (US$ Million)
    Table 34. North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2021) (US$ Million)
    Table 35. North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2022-2027) & (US$ Million)
    Table 36. North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2016-2021) & (US$ Million) 
    Table 37. North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2022-2027) & (US$ Million) 
    Table 38. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021) (US$ Million)
    Table 39. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2022-2027) & (US$ Million)
    Table 40. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2021) (US$ Million)
    Table 41. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2022-2027) & (US$ Million)
    Table 42. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2016-2021) & (US$ Million) 
    Table 43. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2022-2027) & (US$ Million) 
    Table 44. Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021) (US$ Million)
    Table 45. Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2022-2027) & (US$ Million)
    Table 46. Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Region (2016-2021) & (US$ Million) 
    Table 49. Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Region (2022-2027) & (US$ Million) 
    Table 50. Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021) (US$ Million)
    Table 51. Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2022-2027) & (US$ Million)
    Table 52. Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2021) (US$ Million)
    Table 53. Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2022-2027) & (US$ Million)
    Table 54. Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2016-2021) & (US$ Million) 
    Table 55. Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2022-2027) & (US$ Million) 
    Table 56. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2016-2021) (US$ Million)
    Table 57. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Type (2022-2027) & (US$ Million)
    Table 58. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Application (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2016-2021) & (US$ Million) 
    Table 61. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size by Country (2022-2027) & (US$ Million) 
    Table 62. Alkermes Plc Company Details
    Table 63. Alkermes Plc Business Overview
    Table 64. Alkermes Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product
    Table 65. Alkermes Plc Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021) & (US$ Million)
    Table 66. Alkermes Plc Recent Development
    Table 67. Allergan Plc Company Details
    Table 68. Allergan Plc Business Overview
    Table 69. Allergan Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product
    Table 70. Allergan Plc Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021) & (US$ Million)
    Table 71. Allergan Plc Recent Development
    Table 72. Bristol Myers Squibb Co. Company Details
    Table 73. Bristol Myers Squibb Co. Business Overview
    Table 74. Bristol Myers Squibb Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product
    Table 75. Bristol Myers Squibb Co. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021) & (US$ Million)
    Table 76. Bristol Myers Squibb Co. Recent Development
    Table 77. Eli Lilly& Co. Company Details
    Table 78. Eli Lilly& Co. Business Overview
    Table 79. Eli Lilly& Co. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product
    Table 80. Eli Lilly& Co. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021) & (US$ Million)
    Table 81. Eli Lilly& Co. Recent Development
    Table 82. GlaxoSmithKline Plc Company Details
    Table 83. GlaxoSmithKline Plc Business Overview
    Table 84. GlaxoSmithKline Plc Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product
    Table 85. GlaxoSmithKline Plc Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021) & (US$ Million)
    Table 86. GlaxoSmithKline Plc Recent Development
    Table 87. H. Lundbeck Company Details
    Table 88. H. Lundbeck Business Overview
    Table 89. H. Lundbeck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product
    Table 90. H. Lundbeck Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021) & (US$ Million)
    Table 91. H. Lundbeck Recent Development
    Table 92. Merck Company Details
    Table 93. Merck Business Overview
    Table 94. Merck Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product
    Table 95. Merck Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021) & (US$ Million)
    Table 96. Merck Recent Development
    Table 97. Pfizer Company Details
    Table 98. Pfizer Business Overview
    Table 99. Pfizer Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021) & (US$ Million)
    Table 100. Pfizer Recent Development
    Table 101. Teva Pharmaceutical Industries Ltd. Company Details
    Table 102. Teva Pharmaceutical Industries Ltd. Business Overview
    Table 103. Teva Pharmaceutical Industries Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product
    Table 104. Teva Pharmaceutical Industries Ltd. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021) & (US$ Million)
    Table 105. Teva Pharmaceutical Industries Ltd. Recent Development
    Table 106. Takeda Pharmaceutical Co. Ltd. Company Details
    Table 107. Takeda Pharmaceutical Co. Ltd. Business Overview
    Table 108. Takeda Pharmaceutical Co. Ltd. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Product
    Table 109. Takeda Pharmaceutical Co. Ltd. Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021) & (US$ Million)
    Table 110. Takeda Pharmaceutical Co. Ltd. Recent Development
    Table 111. Research Programs/Design for This Report
    Table 112. Key Data Information from Secondary Sources
    Table 113. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Type: 2020 VS 2027
    Figure 2. Nonselective MAO-Ainhibitors Features
    Figure 3. Selective MAO-B inhibitors Features
    Figure 4. Nonselective MAO-B inhibitors Features
    Figure 5. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Application: 2020 VS 2027
    Figure 6. Depression Treatment Case Studies
    Figure 7. Parkinson's Disease Treatment Case Studies
    Figure 8. Other Therapy Case Studies
    Figure 9. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Report Years Considered
    Figure 10. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 11. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 12. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Regions: 2020 VS 2027
    Figure 13. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Regions (2022-2027)
    Figure 14. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Players in 2020
    Figure 15. Global Top Reversible Inhibitors of Monoamine (RIMA) Antidepressants Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Reversible Inhibitors of Monoamine (RIMA) Antidepressants as of 2020
    Figure 16. The Top 10 and 5 Players Market Share by Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue in 2020
    Figure 17. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Type (2016-2021)
    Figure 18. Global Reversible Inhibitors of Monoamine (RIMA) Antidepressants Revenue Market Share by Type (2022-2027)
    Figure 19. North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 20. North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Type (2016-2027)
    Figure 21. North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Application (2016-2027)
    Figure 22. North America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Country (2016-2027)
    Figure 23. United States Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Canada Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Type (2016-2027)
    Figure 27. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Application (2016-2027)
    Figure 28. Europe Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Country (2016-2027)
    Figure 29. Germany Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. France Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. U.K. Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Italy Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Russia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Nordic Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Type (2016-2027)
    Figure 37. Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Application (2016-2027)
    Figure 38. Asia-Pacific Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Region (2016-2027)
    Figure 39. China Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. Japan Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. South Korea Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Southeast Asia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. India Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Australia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Type (2016-2027)
    Figure 47. Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Application (2016-2027)
    Figure 48. Latin America Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Country (2016-2027)
    Figure 49. Mexico Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Brazil Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Type (2016-2027)
    Figure 53. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Application (2016-2027)
    Figure 54. Middle East & Africa Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Share by Country (2016-2027)
    Figure 55. Turkey Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. Saudi Arabia Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. UAE Reversible Inhibitors of Monoamine (RIMA) Antidepressants Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Alkermes Plc Revenue Growth Rate in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
    Figure 59. Allergan Plc Revenue Growth Rate in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
    Figure 60. Bristol Myers Squibb Co. Revenue Growth Rate in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
    Figure 61. Eli Lilly& Co. Revenue Growth Rate in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
    Figure 62. GlaxoSmithKline Plc Revenue Growth Rate in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
    Figure 63. H. Lundbeck Revenue Growth Rate in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
    Figure 64. Merck Revenue Growth Rate in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
    Figure 65. Pfizer Revenue Growth Rate in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
    Figure 66. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
    Figure 67. Takeda Pharmaceutical Co. Ltd. Revenue Growth Rate in Reversible Inhibitors of Monoamine (RIMA) Antidepressants Business (2016-2021)
    Figure 68. Bottom-up and Top-down Approaches for This Report
    Figure 69. Data Triangulation
    Figure 70. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Alkermes Plc
Allergan Plc
Bristol Myers Squibb Co.
Eli Lilly& Co.
GlaxoSmithKline Plc
H. Lundbeck
Merck
Pfizer
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Co. Ltd.
Frequently Asked Questions
Reversible Inhibitors of Monoamine (RIMA) Antidepressants report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Reversible Inhibitors of Monoamine (RIMA) Antidepressants report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Reversible Inhibitors of Monoamine (RIMA) Antidepressants report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports